Toxicities and associated factors in patients receiving
temozolomide-containing regimens: a 12-year analysis of hospital data
Abstract
Background: Although temozolomide has been extensively used to treat
various tumors, there is a lack of large-cohort studies on
temozolomide’s toxicity profile. Objective: To analyze the toxicity
profiles and associated factors in patients treated with
temozolomide-containing regimens. Setting: The Union Hospital of Tongji
Medical College, Huazhong University of Science and Technology. Methods:
A retrospective analysis of the clinical data of patients treated with
temozolomide-containing regimens from January 2008 to December 2019.
Univariate chi-square test and multivariate logistic regression analysis
were employed to identify factors associated with the occurrence of
toxicities. Main outcome measure: The rate of toxicity occurrence and
the characteristics of the toxicities. Results: Among the 1,057 patients
received temozolomide-containing regimens, 922 patients were included in
our analyses. Of the 922 patients, 484 patients (52.5%) experienced
toxicities. Univariate analysis revealed that radiotherapy, chemotherapy
cycle, chemotherapy regimen, and clinical stage were significantly
associated with the toxicity during temozolomide treatment (P
< 0.05). The chemotherapy regimen, chemotherapy cycle, and
clinical stage were significantly associated with the overall occurrence
of toxicities (P < 0.05). A chemotherapy regimen, chemotherapy
cycle, and clinical stage were associated with the hematological
system’s toxicities, whereas gender, age, clinical diagnosis, and
clinical stage were related to gastrointestinal toxicities (P
< 0.05). Clinical diagnosis, chemotherapy regimen, and age
were associated with liver toxicity (P < 0.05). Conclusion:
Toxicities are common among patients receiving temozolomide-containing
regimens. Clinicians should be aware of factors associated with
toxicities to minimize the impact of the toxicity.